Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06887348 · ClinicalTrials.gov registry record
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
A clinical trial of Melanoma and Advanced Solid Tumor, sponsored by Replimune.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT06887348 is a study of Melanoma and Advanced Solid Tumor that is actively recruiting participants, run by Replimune. The registered enrollment target is 50 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06887348, a study of Melanoma and Advanced Solid Tumor, is actively recruiting participants, sponsored by Replimune.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.
Conditions Studied
Interventions
- OTHER Observational study with no interventions
Study Locations (2)
California
- UC San Diego Moores Cancer Center - La Jolla
Queensland
- Tasman Oncology Research - Southport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06887348
The ClinicalTrials.gov registry entry for NCT06887348 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is Replimune, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Observational study with no interventions is the first listed.
NCT06887348 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Queensland.
Frequently Asked Questions
What is clinical trial NCT06887348 about?
NCT06887348 is a clinical study titled "A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3". This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose o...
What is the current status of trial NCT06887348?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-12-12. Estimated completion is 2035-12.
What conditions does trial NCT06887348 study?
This clinical trial studies the following conditions: Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma, Metastatic Melanoma.
What interventions are being tested in trial NCT06887348?
The interventions under investigation include: Observational study with no interventions (OTHER).
Who is sponsoring clinical trial NCT06887348?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06887348 being conducted?
This trial has 2 study locations across California, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.